Literature DB >> 12139239

Chemiluminescent measurement of telomere DNA content in biopsies.

Colleen A Fordyce1, Christopher M Heaphy, Jeffrey K Griffith.   

Abstract

Telomeres are nucleoprotein complexes that protect the ends of chromosomes from fusion and degradation. They are typically shorter in tumor cells than in paired normal cells, and shorter telomeres are associated with poor outcome in cancer. We previously described a slot blot-based methodfor measuring telomere DNA content, a proxy for telomere length. Although this method represented an improvement over existing methods, its 30-ng limit of sensitivity was insufficient for use with biopsy or other scant tissues. Here we describe a chemiluminescent slot blot assay for telomere DNA content that has the sensitivity required for use with biopsy materials. The results obtained with DNA derived from human placental, HeLa, human peripheral blood lymphocytes, sham-needle core prostate biopsies, and archival prostatectomy tissues demonstrated that telomere DNA content can be reliably and reproducibly measured in 5 ng, and sometimes as little as 2 ng, genomic DNA. Sham-needle core prostate biopsy and prostatectomy specimens processed in parallel produced comparable results. The contribution of truncated telomeres in admixtures containing as much as 75% normal placental DNA could be established. We also demonstrated that the treatment of tissue with formalin before DNA purification does not decrease the efficacy of the assay.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139239     DOI: 10.2144/02331md02

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  7 in total

Review 1.  Luminol-based chemiluminescent signals: clinical and non-clinical application and future uses.

Authors:  Parvez Khan; Danish Idrees; Michael A Moxley; John A Corbett; Faizan Ahmad; Guido von Figura; William S Sly; Abdul Waheed; Md Imtaiyaz Hassan
Journal:  Appl Biochem Biotechnol       Date:  2014-04-22       Impact factor: 2.926

2.  Organ-wide telomeric status in diseased and disease-free prostatic tissues.

Authors:  Christopher M Heaphy; Trisha M Fleet; Eric G Treat; Sang-Joon Lee; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi
Journal:  Prostate       Date:  2010-09-15       Impact factor: 4.104

3.  DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.

Authors:  Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-22

4.  Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer.

Authors:  Eric G Treat; Christopher M Heaphy; Larry W Massie; Marco Bisoffi; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith
Journal:  Urology       Date:  2009-07-16       Impact factor: 2.649

5.  Measurement of telomere DNA content by dot blot analysis.

Authors:  Masayuki Kimura; Abraham Aviv
Journal:  Nucleic Acids Res       Date:  2011-04-27       Impact factor: 16.971

Review 6.  The potential utility of telomere-related markers for cancer diagnosis.

Authors:  Christopher M Heaphy; Alan K Meeker
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

7.  Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.

Authors:  Kimberly S Butler; William C Hines; Christopher M Heaphy; Jeffrey K Griffith
Journal:  Cancer Med       Date:  2012-07-24       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.